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THE ROLE OF PRESCRIPTION TRENDS IN
THE OPIOID EPIDEMIC AND THE
FACTORS THAT AFFECT
PHYSICIAN PRESCRIPTIONS
Ashley N. Beals
Dr. Jeffrey Schulz, Mentor
ABSTRACT
Every day, more than 90 Americans die as a result
of opioid overdose (NIH, 2017a), and opioid overdoses have
quadrupled since 1999 (CDC, 2016). Opioids are best described
as a class of drug that includes synthetic versions, such as fentanyl,
the commonly known illegal drug, heroin, and prescribed
medications such as oxycodone (OxyContin®) and hydrocodone
(Vicodin®; NIH, 2017b). Opioids directly activate the analgesia,
or pain relieving portion of the brain as well as the reward region
(Volkow & McLellan, 2016). This makes the drug effective
for reducing pain as well as giving the body a sense of reward.
However, the drug manipulates the reward system by building a
learned association between taking the drug and the satisfactory
effect received from the drug (Volkow & McLellan, 2016). This
learned association puts the patient or user at risk for misuse of
the drug, making opioid prescribing difficult for physicians. Other
factors affecting opioid prescribing are racial disparities, patientphysician mistrust, pain perception, and the difference between
acute and chronic pain (Mathur, Richeson, Paice, Muzyka,
& Chiao 2014; Volkow & McLellan, 2016). The purpose of
this article is to explore the factors that affect physicians’
decisions to prescribe opioids, and to examine how
prescription trends influence the opioid epidemic.
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LITERATURE REVIEW
Opioids are a significant tool utilized by physicians for
their pain relieving, or analgesic, effect. Opioids produce their
analgesic effect by binding to mu-opioid receptors in the brain.
Mu-opioid receptors are primarily located in the thalamus,
periaqueductal gray, insula, anterior cingulate (region associated
with pain perception), ventral tegmental area, nucleus accumbens
(region associated with reward), amygdala (region associated with
emotional regulation and memory), and the brainstem (nuclei that
regulates breathing; Volkow & McLellan, 2016). The location of
mu-opioid receptors demonstrates how opioids are able to relieve
pain and present euphoria.
The mu-opioid receptors located in the brainstem are
responsible for the suppressed breathing characterized in opioidrelated overdose. In addition to activating the analgesic and reward
regions of the brain, opioids also create a learned association
between receiving the drug and the effect of the drug (Volkow &
McLellan, 2016). This learned association happens fairly quickly
and puts the user at risk for developing a dependence.
Substances derived from opium can be placed into
two categories: those directly derived from opium, and those

Figure 1. Opioids, divided by classification.
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derived from morphine, which is more potent than simple
opium (Opium, 2016). Another category of derivatives does not
contain opium, but is synthetic and made to mimic the effects
of opium. Drugs derived directly from opium include codeine
and morphine; drugs derived from morphine or other derivatives
include heroin, oxycodone, hydrocodone, and hydromorphone.
Common synthetic versions of opium are methadone, fentanyl,
fentanyl duragesic patches, propoxyphene, butorphanol, and
levorphanol (Figure 1; Opium, 2016).

Prescribing Methods as a Factor in the Opioid Epidemic
Trends in Opioid Prescriptions.
Opioid overdose and the prescription of opioids have
a parallel relationship. There were 52,404 deaths from drug
overdose reported in the United States in 2015, and 63.1% were
opioid related (Guy et al., 2017). Since the 1990s, opioid sales and
prescriptions have quadrupled (Kunins, 2015). The commonly
prescribed drugs oxycodone, methadone, hydrocodone, and other
semisynthetic drugs accounted for a 9% increase in overdoses
(Lucyk & Nelson, 2017).
A letter published in 1980 in the New England Journal
of Medicine may have sparked this sharp increase in opioid
sales and prescriptions. Hershel Jick, a physician at the Boston
University School of Medicine, submitted a letter to the editor,
published under the title, “Addiction Rare in Patients Treated with
Narcotics” (Quinones, 2016). Using data collected by the Boston
Collaborative Drug Surveillance Program, Jick analyzed patient
records to determine whether the patients developed an addiction
after taking prescribed narcotic painkillers. Jick concluded that,
out of the almost 12,000 patients who were treated with opiates in
a hospital setting, only four had developed an addiction (Quinones,
2016). Jick did not disclose information about the dosage the
patients received, the duration they received the medication, or
how often it was administered. The letter read:
To the Editor...The addiction was considered major
in one instance. The drugs implicated were meperidine in two patients, Percodan in one, and hydromor-
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phone in one. We conclude that despite widespread
use of narcotic drugs in hospitals, the development
of addiction is rare in medical patients with no history of addiction. (Porter & Jick, 1980, p. 123)
Jick did not make scientifically verified claims, however, his words were routinely cited as actual evidence
that addiction was unlikely to occur when a patient
without a history of addiction received opioids in a
clinical setting. By 1990, Jick’s pronouncement became
revolutionary in the medical world, and influenced prescribing methods in hospitals, medical clinics, and family practices throughout the nation (Quinones, 2016).
Similarly, Purdue Pharma, a pharmaceutical company,
claimed a drug they created, OxyContin, had a lower possibility for
abuse than other oxycodone products. Purdue wanted their product
to be marketed with an emphasis on the benefits for cancer patients
(Quinones, 2016). In 1996, Purdue used aggressive and persistent
strategies to promote OxyContin; their strategies proved effective,
and sales rose from $48 million in 1996 to $1.1 billion in 2000
(Van Zee, 2009). As reported by Van Zee (2009), a major goal of
Purdue’s marketing plan was to increase physician prescribing
of OxyContin. Purdue tailored their presentation of the drug to
individual physicians by researching the physician’s background
and prescribing practices. Highly paid physicians with a high rate
of opioid prescriptions became targets for Purdue, whose sale
representatives were told to report that the risk of addiction to
OxyContin was “less than one percent” (Van Zee, 2009, p. 223).

Financial ties.
Purdue Pharma and other pharmaceutical industries may
have influenced the opioid epidemic through financial relationships
with opioid-related advocacy groups and physicians. According
to the U.S. Senate Homeland Security and Governmental Affairs
Committee (HSGAC, 2018), Purdue has paid about $4.2 million
dollars to patient advocacy groups, greatly increasing the sales
of their products. Figure 2 shows the amount Purdue Pharma and
other pharmaceutical companies paid to patient advocacy groups
between 2012 and 2017, a figure of more than $8.9 million dollars.
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Despite their success, Purdue Pharma and many other drug
manufacturers have come under fire for their aggressive marketing.
Purdue, in particular, has received criticism for misrepresenting
OxyContin to physicians as non-addictive. In 2007, an affiliate
of Purdue Pharma, Purdue Frederick Company Inc., and its three
top executives, were charged for the misbranding of OxyContin
(Van Zee, 2009). According to Van Zee (2009), the increased rate
of OxyContin abuse was a leading factor in the growing trend
of prescription opioid abuse. While Purdue Pharma has eased up
on their aggressive marketing techniques, ongoing financial ties
between advocacy groups and professional societies suggest a
continuing effort to promote opioid use (HSGAC, 2018).

Figure 2. Payment amounts from pharmaceutical companies to patient advocacy groups.
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Figure 3. Annual morphine prescribing rates, 2006-2015.

Trends.
The prescribing of opioids leveled off from 2010 to 2015,
decreasing the amount of opioid prescriptions, yet the United
States has seen an increase in opioid availability (Lucyk & Nelson,
2017), and the prescribing rates are still three times the number of
1999 (Centers for Disease Control and Prevetion [CDC], 2017).
Figure 3 shows the annual prescribing rate from 2006 to 2015 in
morphine milligram equivalents (MME). In addition to the high
prescribing rate, the prescription length increased from a 13.3 day
supply in 2006 to 17.7 days in 2015 (Guy et al., 2017). According
to Lucyk and Nelson (2017), the use of heroin and synthetic
opioids, such as fentanyl, is the primary cause of the continually
increasing rates of overdose.
The CDC (2017) report that, although there are various
ways to obtain opioids, those who use them non-medically for
more than 200 days a year are at the greatest risk for overdose.
Figure 4 illustrates the sources of opioids for non-medical use:
prescriptions (27%), friends and family (not purchased; 26%),
friends and family (purchased; 23%), and purchasing from a
dealer (15%).
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Figure 4. Sources of opioids for non-medical use.

Trends in opioid overdose.
The U.S. faced similar drug crises in the 1970s with heroin
and the cocaine epidemic of the 1980’s. The National Center
for Health Statistics (NCHS) reports that the opioid epidemic is
more sustained, has reached larger regions, and has had greater
socioeconomic reach than previous epidemics (National Academy

Figure 5. Opioid deaths, 1970 - 2015.
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of Sciences [NAS], 2017). Figure 5 shows the significant increase
in deaths from overdoses over time; the opioid period has had the
most deaths per 100,000 compared to previous drug epidemics.

Fentanyl overdoses on the rise.
Fentanyl is a synthetic opioid used for treating pain,
especially cancer pain, and has become a major cause of synthetic
opioid deaths when produced and obtained illicitly. According
to the CDC (2017), fentanyl is 50-100 times more potent than
morphine and is often mixed with heroin and cocaine when
illicitly produced. From 2014 to 2015, there was a 196% increase
in fentanyl-related overdoses (Figure 6).

Figure 6. Opioid deaths by drug type, 2015 - 2017.

Misuse of Buprenorphine.
Buprenorphine is a semi-synthetic opioid prescribed to
help treat opioid dependence. First thought to have a low risk of
addiction, Buprenorphine tablets are water soluble, making them
convenient for intravenous use. Buprenorphine misuse is common
among opioid-dependent individuals (Moratti, Kashanpour,
Lombardelli, & Maisto, 2010).

Naloxone to treat overdoses.
Naloxone is a medication used to reverse an opioid
overdose by binding to opioid receptors and blocking or reversing
20
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the effect of other opioids (National Institutes of Health [NIH],
2018). As reported by the National Institute on Drug Abuse
(NIDA), Naloxone is an extremely safe, prescribed medication
usually administered by a paramedic via injection; there is now a
nasal spray available under the brand name NARCAN®.

Patient-Clinician Mistrust and Pain Perception
Today, many physicians express concerns regarding
how to prescribe opioids in a safe manner, detect early signs
of addiction, and discuss substance abuse/dependency with
their patients (Volkow & McLellan, 2016). Mistrust between
patients and physicians poses a particular problem. In a series of
patient and physician interviews, Buchman, Ho, and Illes (2016)
evaluated patient and clinician viewpoints, clinicians’ trust of their
patients, and patients’ concerns that they appear “untrustworthy”
to clinicians. Clinicians fear that they will be subjected to false
injury claims made by patients to obtain opioid medications, which
they describe as “being burned” (Buchman et al., 2016, p. 1400).
One physician stated, “We have a responsibility to be careful with
prescribing these medications, [for] when we get burned, society
gets burned, patients get burned” (Buchman et al., 2016, p. 1400).
Many patients experience difficulties in communicating
their pain and may fear their pain will go untreated (Buchman et
al., 2016). Buchman et al. (2016) identified a number of problems
in patient/physician communication in relation to pain treatment.
First, some patients feared their pain would worsen as a result of
their physician dismissing the importance of their pain; second,
some patients experienced difficulties in accurately describing
their pain level to medical practitioners. Third, some patients did
not trust their physician because they believed their physician did
not trust them, and the fourth problem arose from the stigmas faced
by patients who had experienced previous substance abuse and
were viewed as addicts, even if they no longer abused substances.
Buchman et al. (2016) found that physicians reported
difficulties prescribing medications for chronic pain due to
their patients having come from a different background. Many
physicians were concerned that some patients were only seeking
medication to support a substance use disorder; physicians also
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reported they were wary about prescribing addictive medications,
such as opioid analgesics. They felt the need to be extra cautious
about the veracity of the patient’s reported symptoms, which led
to mistrust in the physician-patient relationship.

Neuroanatomy of pain perception.
Pain intensity, caused by a nociceptive process, can be very
difficult for patients to describe accurately to their physician. The
nociceptive process begins when an individual comes into contact
with harmful stimuli, either externally or internally. A message
is then sent by neural pathways from injured tissue, through the
peripheral nervous system, to the central and autonomic nervous
system (Garland, 2012). Physical, cognitive, and emotional
factors play a role in the nociceptive process and help adjust the
pain intensity (Tracey, 2008).
Differences exist between nociception and clinical pain.
Nociception is a neural process that can result in tissue damage,
compared to clinical pain, which is pain described by patients
who are interpreting their perception of the nociception process
occurring in their body (Mao, 2012).

Acute and chronic pain.
The biggest difficulty in pain management is effectively
prescribing opioids for chronic pain, and particularly non-cancer
chronic pain. Opioids are most effective when treating acute pain,
which is pain expected to last less than six months. In general,
opioids are no longer needed once the underlying cause no longer
exists (Cleveland Clinic, 2017). Opioids can help to relieve acute
pain while improving functions, however, the benefits of opioids
for long-term chronic pain management are uncertain (Volkow
& McLellan, 2016). Opioid analgesics and non-steroidal antiinflammatory drugs (NSAIDs) can help cut or shorten the acute
pain caused by surgery or trauma, while opioids and NSAIDs
lessen pain by cutting the nociceptive input short (Mao, 2012).
Chronic pain may continue, even when the underlying
cause (i.e., surgery or injury) no longer exists (Cleveland Clinic,
2017). The mismatch between nociception and chronic pain makes
treating chronic pain in a clinical setting difficult; a mismatch arises
22
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when chronic pain is influenced by psychosocial factors, such as
depression and anxiety (Mao, 2012). Such comorbid psychosocial
factors can result in a higher perceived pain level in patients.
Chronic pain has a 40% prevalence rate in U.S. older
American adults and explains why prescribing opioids has
become an issue in the U.S. (Volkow & McLellan, 2016). There
are approximately 100 million Americans with chronic pain, and
pain management costs the U.S. some $560-635 billion dollars a
year (Institute of Medicine [IOM], 2011). According to Guy et al.
(2017), three main reasons explain the sharp increase in opioid
prescriptions: first, an increase of opioid prescriptions for chronic
pain, specifically chronic non-cancer pain; second, extended
durations over which opioids are prescribed; and third, higher
dosages of opioids prescribed for patients with chronic pain, over
extended lengths of time.

Racial Disparities as a Factor in the Opioid Epidemic
Statistics of race and use.
The Henry J. Kaiser Family Foundation (2017) analyzed
2015 overdose data from the CDC’s National Vital Statistics
System. In the U.S., there were a total of 33,091 deaths from
opioids, natural and synthetic; the majority of the deceased
were White, Non-Latino Americans, with 27,056 deaths. Black
and Latino populations experienced significantly fewer deaths
from opioid overdose: 2,741 overdose deaths within the Black
population and 2,507 overdose deaths within the Latino population.
Figure 7 shows the deaths per 100,000 for non-Hispanic White,
non-Hispanic Black, and Hispanic individuals.
The differences in opioid overdose deaths between White and
non-White populations were discussed in a 2017 interview with Noel
King, National Public Radio (NPR) host, and Dr. Andrew Kolodny, a
drug abuse expert (NPR, 2017). Kolodny believed these differences
in numbers are a result of prescribing methods; physicians are often
more cautious when they prescribe addictive medication to non-White
patients than to White patients. Kolodny explained that this caution
stems from the belief that Black and Latino patients are more likely
to abuse and become addicted to the medication. Physicians may be
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Figure 7. Drug overdose deaths by race and ethnicity, 1999 - 2015.

unaware of this racial bias because it happens on an unconscious level.
Comparing the current opioid epidemic to the cocaine epidemic of
the 1980’s, which largely affected the low-income Black population,
Kolodny pointed out that the responses to each were different. Cocaine
abusers were arrested and incarcerated; the response to the current
opioid epidemic, which targets a largely White population, is to ensure
proper treatment to those with a drug dependency.

Provider bias.
Compared to White patients, non-White patients are less
likely to receive quality pain treatment (Mathur, Richeson, Paice,
Muzyka, & Chiao, 2014). This issue has, ironically, served as
a protective factor for minority populations. In a study done in
Michigan, researchers examined the differences in prescription
opioid availability in pharmacies located in zip codes that
were either predominantly White or minority. From previous
research, the article established that a physician’s method of
pain management varied on the type of pain and the patient’s
demographics. Green, Ndao-Brumblay, Khady, West, and
Washington (2005) stated that, “Physicians reported lesser goals
for chronic pain, and their prescribing habits differed on the basis
of race, ethnicity, age, and gender, with the pain complaints of
minorities, elderly persons, and women receiving less attention
than the complaints of white men” (p. 689). When collecting and
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analyzing variability data, researchers found that pharmacies in
primarily White neighborhoods were more likely to carry opioid
analgesic than those in minority neighborhoods.
In the Michigan study, Green et al. (2005) selected zip
codes with at least 70% minority residents and zip codes with more
than or equal to 70% White residents. They examined the racial
composition of 965 zip codes and found that only 3.4% of the zip
codes had a composition that could not be classified to a majority
race. After sampling and excluding pharmacies that had missing
information or were unresponsive, 93 minority pharmacies and 95
White pharmacies were included in the analysis.
The researchers contacted the managers of the pharmacies
via phone and asked them about the availability of 15 common
opioid analgesics at their location. The 15 common opioid
analgesics fall into three categories of opioids: long-acting, shortacting, and combination products. The researchers collected data
on the quantities of opioid analgesics the pharmacies carried and
noted the reasons why some pharmacists carried low quantities
of opioids: (1) low demand, (2) concerns about illicit use, (3) too
much paperwork, (4) fear of robbery, (5) lack of directions on
drug disposal, and (6) “other” (Green et al., 2005).
The study found that pharmacies in predominantly White
zip codes were more likely to have sufficient supplies of opioids
than in minority zip codes (Green et al., 2005). The study also
examined distances between pharmacies and hospitals and found
no correlation between the pharmacy’s distance from a hospital
and its opioid stock. Researchers also found that non-corporate
pharmacies were more likely to have sufficient supplies of opioids
than corporate pharmacies.
Pharmacies with low opioid supplies reported that low
demand was the main reason. Paperwork and fear of robbery
were not major reasons for this choice. Those with a sufficient
supply were less likely to report concerns about illicit opioid use
than pharmacies that did not have a sufficient supply (Green et
al., 2005). Overall, the study found significantly less access to
opioids in minority zip codes than White zip codes, regardless
of the community’s income level. However, when not comparing
race, low-income areas were less likely to have access to sufficient
opioid supplies than higher income regions (Green et al., 2005).
25
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Racial priming.
Another method used to gauge how race can impact an
individual’s perception is racial priming. Racial priming is a way
to influence a bias or perception by revealing the race of another at
either a subconscious or relatively conscious level (Mendelberg,
2008). Mathur et al. (2014) used racial priming to observe
participants’ reaction to pain experienced by different races. The
sample included 324 student volunteers. The volunteers were
asked to pretend they worked at their university’s student health
center and to review patient reports. The reports had a description
of the patient’s reason for visiting, as well as a facial photograph.
To test for implicit racial priming, the face of either a
Black or White male was flashed on a screen for no more than
30 milliseconds. This was considered long enough to influence
the respondents’ perception of the patient, but too short for the
respondent to identify exactly what they saw. To make use of
explicit facial priming, the image of either a Black or White male

Figure 8. Implicit and explicit racial bias priming.
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was presented to the respondent for a full seven seconds (Figure
8; Mathur et al., 2014).
In addition to reviewing reports, respondents completed a
seven question survey regarding the reports. The survey consisted
of an 11-point Likert scale (0=not at all and 10=very much;
Mathur et al., 2014). The questions focused on pain perception
(“How much pain do you think the patient is experiencing?”),
empathy (“Do you feel bad for the patient?), helping motivation
(likeliness of respondent helping the patient), excused absence
(“Do you think the patient should be excused from class/exam?”),
treatment recommendation, perceived trustworthiness (“Is the
patient trustworthy?”), and perceived responsibility (“Do you
think the patient is responsible for their own pain?”).
According to Mathur et al. (2014), the researchers’ study,
which used two races and two prime conditions, explicit and
implicit prime, showed a major relationship between prime type
and the race of the primed patient; there were more responses to
the perceived pain of the Black male patients in explicit priming
and more responses to the perceived pain of White male patients
in the implicit priming. The researchers also noted that the sex of
the volunteer was of interest; female volunteers tended to respond
more to the pain of all of the patients than male volunteers. As far
as race, researchers did not expect the volunteers to respond more
to Black male patient pain in the explicit prime report, where the
race of the patient was made more obvious. Researchers propose
this was likely due to the fact the volunteer was more conscious
and did not want to appear to be prejudiced or biased.

Recommendations for Prescribing: The Michigan Prescription Drug and Opioid Task Force
Education and training.
The Michigan Prescription Drug and Opioid Task Force
(2015) recommends that medical professionals should receive
training on how to treat patients using opioids and how to treat
addiction to opioids and other substances. The Task Force
sees education and training as the best model for opioid abuse
prevention.
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Reducing prescriptions.
The Task Force (2015) recognizes the need for a collaborative
relationship between stakeholders and state government for
reducing opioid and prescription drug abuse. A collaborative effort
from state and local agencies is needed to provide information about
prescription drug abuse, preventions, and treatment. Reductions in
the overall prescribing of opioids are also recommended. Effective
interventions for reducing the amount of unused medication include
the availability of drop-off bins, where unused medications can be
disposed of in a safe, convenient manner, and take-back programs,
which can help increase public awareness of the importance of
unused medication disposal.
The Task Force (2015) also recognizes the need to address
individuals who are dealing with substance dependency and are
seeking prescription drugs for non-medical use. These individuals
engage in what is called pharmacy shopping, when they go from
one pharmacy to another, often seeing several doctors to try to
obtain multiple prescriptions. One way to address this is to “lockin” the prescription, making it difficult to refill more than once. In
addition, limiting patients to a single doctor or pharmacy may be
another way to address pharmacy shopping.

Raising awareness.
The Task Force (2015) reports that public understanding of
opioid and prescription abuse is low and recommends campaigns
to help raise awareness. Campaigns should address risks associated
with abuse, how to dispose of unused medications safely and
properly, as well as informing the public about prescribing practice
etiquette and aiming to reduce stigma around addiction.

CONCLUSION
Prescribing practices have been a major influence on
our nation’s current opioid epidemic. Factors, such as racial
disparities, patient-physician mistrust, pain perception, and the
differences between acute and chronic pain, have affected opioid
prescribing practices. There is a critical need to address the patient
experience when administering prescriptions with a potential risk
for substance abuse, especially in patients who have experienced
substance abuse in the past.
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Large pharmaceutical companies and inaccurate claims
that minimize the dangers of opioid dependency have increased
the potential for opioid addiction. Although we have had success in
decreasing availability of opioid prescriptions, we must now face the
issue of heroin use and the misuse of Buprenorphine. It is imperative
that we address these issues through education and training, reducing
prescriptions, and raising awareness of the problem.
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